Pilot Randomized Trial of a Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer.

J Pain Symptom ManageMay 30, 2026 (epub)
Clinical ResearchOncology (Medical)GastroenterologyOpen access

Kelsey S Lau-Min, Riley Psenka, Mia Holtze et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the feasibility and acceptability of the PATHWAYS supportive care intervention for patients starting multimodality therapy for locally advanced rectal cancer (LARC). Among 20 enrolled patients, 90% of those receiving PATHWAYS completed the intervention, with 100% reporting it as acceptable. The study highlights the potential for tailored support in this patient population.

Key findings

  • 59% of eligible patients enrolled in the study.
  • 90% of PATHWAYS participants completed the intervention.
  • 100% of PATHWAYS participants found the intervention acceptable.

Why it matters

The complexity of multimodality therapy for LARC can overwhelm patients. Effective supportive care interventions like PATHWAYS may enhance patient engagement and satisfaction, potentially improving overall treatment experiences.

Source

PubMed · PMID 42217757Free full text on PubMed Central

Published in J Pain Symptom Manage. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.